In the eye of the B-holder: Natural history of chronic hepatitis B

Hepatology

Volumn 58, Issue 1, 2013, Pages 6-8

  Pungpapong, Surakit ^a   Kim, W Ray ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADVERSE OUTCOME; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; BLOOD DONOR; CHINESE; CHRONIC LIVER DISEASE; CONCURRENT INFECTION; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; END STAGE LIVER DISEASE; ENDEMIC DISEASE; HEPATITIS B; HEPATITIS C; HEPATITIS DELTA VIRUS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; MORTALITY; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH PROBLEM; SEROCONVERSION; UNITED STATES; VIRUS REPLICATION;

CAUSE OF DEATH; FEMALE; HEPATITIS B; HUMANS; MALE;

EID: 84879604139     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26356     Document Type: Article

References (21)

1. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007; 82: 967-975.
2. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, Chen DS. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276: 906-908.
3. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002; 185: 713-719.
4. Kim WR. Epidemiology of hepatitis B in the United States. HEPATOLOGY 2009; 49(5 Suppl): S28-S34.
5. Szpakowski J-L, Tucker L-Y. Causes of death in patients with hepatitis B: a natural history cohort study in the United States. HEPATOLOGY 2013; 58: 21-30.
6. Villeneuve JP, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106: 1000-1005.
7. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191-194.
8. Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. HEPATOLOGY 1987; 7: 302-306.
9. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognosis factors for chronic hepatitis type B. Gut 1991; 32: 294-298.
10. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. HEPATOLOGY 1995; 21: 77-82.
11. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. HEPATOLOGY 1988; 8: 493-496.
12. Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235-241.
13. Beasley RP, Lin CC, Chien CS, Chen CJ, Hwang LY. Geographic distribution of HBsAg carriers in China. HEPATOLOGY 1982; 2: 553-556.
14. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-1635.
15. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133: 1458-1465.
16. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
17. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
18. Marcellin P, Buti M, Gane EJ, Krastev Z, Flisiak R, Germanidis G, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. HEPATOLOGY 2011; 54: 254A.
19. Gane EJ, Marcellin P, Sievert W, Trinh HN, Shiffman ML, Washington MK, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. HEPATOLOGY 2011; 54: 261A.
20. Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137: 1680-1686.
21. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis b virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308: 1906-1913.